The Code Breaker

Walter Isaacson's 2021 biography of Jennifer Doudna, who shared the 2020 Nobel Prize for co-inventing CRISPR-Cas9, a gene-editing tool adapted from a bacterial immune system. Isaacson traces the discovery from the basic science of how bacteria remember viruses, through the race between Doudna's Berkeley lab and Feng Zhang at the Broad Institute, to the ethical controversies around human germline editing. The book bridges the foundational biology, the patent fight, and the moral questions about editing human embryos.

Gates recommended it on his 2021 holiday reading list, noting that "Isaacson goes into detail about every CRISPR researcher the foundation is supporting (and many others as well)." For a founder, the story is about how a fundamental biology discovery — watching bacteria fight viruses — turned into a technology platform that can rewrite the code of life. The path from Cas9's 2012 publication to clinical trials in under a decade is one of the fastest science-to-application cycles in history.

The race between Doudna's academic lab and Zhang's entrepreneurial one also illustrates a recurring pattern in deep-tech founding: the discoverer is not always the best commercialiser. Doudna and Charpentier published first; Zhang filed patents with broader claims and got the critical ones granted. A founder building on a platform technology should study how intellectual property strategy, not priority of discovery, determined who controls the CRISPR toolbox today.